NMRA · Neumora Therapeutics, Inc.
$0.50
+0.00 (+0.82%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“While the Company expects to be able to obtain additional funding, the current available cash and cash equivalents will not be sufficient to fund the Company’s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$127.32M
Shares
187.90M
Volume · Oct 5
2.99M
Avg daily vol (3M)
1.14M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.50
Open$0.56
Day$0.48–0.56
52W close$0.50–3.59
Avg vol 30d1.5M
Short int7.0M · 3.7% float · 9.0d
Short vol80%
Last earningsMar 30, 2026
DataSep 2023–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
call held Mar 30, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$212.75M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.5%
Year over year · more shares
Price change (1Y)
-71.9%
Trailing year
Short interest
3.7%
Latest settlement · 9.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−74%
below
Price vs 50-day avg
−61%
below
RSI (14)
18
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−63%
trailing
6-month return
−76%
trailing
YTD return
−72%
this year
Relative strength
−88%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +28 funds added
Insider flow
Distributing
Net -$701.6K over 90 days · 100% sells
Short interest
Falling
3.71% of float · ▼ -13.1% MoM · 9.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
114 holders — mid 3-yr range
Squeeze score
47
elevated · 0–100
Fundamentals
EPS growth
+5%
Y/Y
Free cash flow
$-206.6M
Balance sheet
$68.0M
net cash
Quant / Vol
risk profile
Volatility
127%
annualized · 1-yr
Max drawdown
−86%
past year
ATR
19.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−74%
Bearish
Price vs 50-day avg
−61%
Bearish
RSI (14)
18
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +28 funds added
Insider flow
Distributing
Net -$701.6K over 90 days · 100% sells
Short interest
Falling
3.71% of float · ▼ -13.1% MoM · 9.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
114 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $4
vs 200-day avg -74%
vs 50-day avg -61%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NMRA
this stock
Neumora Therapeutics, Inc.
|
$127.32M | -72.1% | — | — | 3.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NMRA | -26.2% | -63.0% | -75.7% | -16.2% | -72.1% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -26.0% | -62.5% | -87.9% | -17.1% | -84.9% |